Evidence mapPaperPMID 42529748Full record

ReviewObesity pillars2026

Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation.

Shashank R Joshi, Anoop Misra, Ambrish Mithal, Banshi Saboo, Krishna G Seshadri, Subhankar Chowdhury, Ganapathi Bantwal, Bipin Sethi, Jothydev Kesavadev, Arpan Dev Bhattacharya and 5 more

Abstract readReview
In one paragraph

Review in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shashank R JoshiDepartment of Endocrinology, Lilavati Hospital, Mumbai, India.
Anoop MisraCentre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, Fortis-C-DOC, Delhi, India.
Ambrish MithalDepartment of Endocrinology & Diabetes, Max Super Speciality Hospital, Delhi, India.
Banshi SabooDepartment of Diabetology, Dia Care, Diabetes Care & Hormone Clinic, Ahmedabad, India.
Krishna G SeshadriDepartment of Endocrinology and Diabetes, Apollo Hospitals, Chennai, India.
Subhankar ChowdhuryDepartment of Endocrinology & Diabetes, Manipal Hospital, Kolkata, India.
Ganapathi BantwalDepartment of Endocrinology, St. John's Medical College, Bengaluru, India.
Bipin SethiDepartment of Endocrinology, CARE Hospitals, Hyderabad, India.
Jothydev KesavadevDepartment of Diabetes and Technologies, Jothydev's Diabetes & Research Center, Trivandrum, India.
Arpan Dev BhattacharyaDepartment of Endocrinology & Diabetes, Manipal Hospital, Bengaluru, India.
Manash P BaruahDepartment of Endocrinology & Diabetes, Apollo Excelcare Hospital, Guwahati, India.
Ajay BudhwarDepartment of Internal Medicine, Dr Ajay Budhwar's Diabetes Clinic, Amritsar, India.
Priti ThakorDepartment of Medical Affairs, Abbott Healthcare Pvt. Ltd., Mumbai, India.
Sachin ShendeDepartment of Medical Services, Abbott Healthcare Pvt. Ltd., Mumbai, India.
Viswanathan MohanDepartment of Diabetology, Madras Diabetes Research Foundation (ICMR- Collaborating Centre of Excellence), Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists, collectively called GLP-based therapies (GBTs), cause gastrointestinal adverse effects and alter dietary intake, leading to nutritional deficiencies and loss of muscle mass and bone density. Therefore, GBTs' use necessitates structured nutritional support, particularly among Asian Indians, given their diverse dietary patterns and high prevalence of sarcopenia. This consensus provides expert-driven, practical recommendations on key nutritional priorities to support the appropriate GBTs' use in individuals with type 2 diabetes mellitus and/or obesity. Methods: This was a consensus-based study using a modified Delphi method with expert panel inputs informed by a literature review. The literature review was conducted before developing statements on challenges experienced by individuals on GBTs and strategies to mitigate micro- and macronutrient deficiencies to guide optimal GBTs' use. A total of 13 domain experts (endocrinologists and diabetologists) across India were included in this process. Results: Among 44 statements (11 sub-statements), 43 received high or moderate consensus, emphasizing the importance of early nutritional assessment and monitoring metabolic outcomes, with a tailored, balanced diet comprising complex carbohydrates, optimal high-quality protein, good-quality fat, micronutrients, and adequate hydration. The panel highlighted calorie-controlled meal replacement, including diabetes-specific nutritional (DSN) formulations, together with sustainable lifestyle practices and resistance exercise to support long-term metabolic health outcomes. After the discontinuation of GBTs, sustained nutritional support may help prevent metabolic rebound. Conclusion: There is a need for structured nutritional support for individuals on GBTs, especially for Asian Indians, considering their dietary pattern and increased risk of sarcopenia. Implementing culturally driven nutritional recommendations, including DSN formula as an adjunct along with lifestyle modifications, can support optimizing long-term patient-centric outcomes. The effectiveness and safety of GBTs, along with newly emerging nutrient-stimulating hormone (NuSH) based therapies, should be evaluated in long-term follow-up studies.

Indexed as

Diabetes specific nutrition formulaDual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-1 receptor agonistGlucagon-like peptide-1 receptor agonistsNutritionObesityType 2 diabetes mellitus

Identifiers

PMID42529748
PMCPMC13418229

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.